Literature DB >> 2204723

Cell-specific differences in activation of NF-kappa B regulatory elements of human immunodeficiency virus and beta interferon promoters by tumor necrosis factor.

J Lacoste1, M D'Addario, A Roulston, M A Wainberg, J Hiscott.   

Abstract

Three aspects of the involvement of tumor necrosis factor in human immunodeficiency virus (HIV) pathogenesis were examined. Tumor necrosis factor alpha (TNF-alpha) mRNA production was analyzed by polymerase chain reaction amplification in monocytic U937 cells and in a chronically HIV infected U937 cell line (U9-IIIB). TNF-alpha RNA was undetectable in U937 cells, whereas a low constitutive level was detected in U9-IIIB cells. Paramyxovirus infection induced a 5- to 10-fold increase in the steady-state level of TNF-alpha RNA in U9-IIIB cells compared with U937 cells, suggesting that HIV-infected monocytic cells produced higher levels of TNF-alpha than did normal cells after a secondary virus infection. The effects of TNF-alpha on gene expression were examined by transient expression assays using reporter chloramphenicol acetyltransferase plasmids linked to regulatory elements from the HIV long terminal repeat (LTR) and the beta interferon promoter. In U937 and Jurkat T lymphoid cells, the inducibility of the different hybrid promoters by TNF-alpha or phorbol ester varied in a cell type- and promoter context-specific manner; the levels of gene activity of NF-kappa B-containing plasmids correlated directly with induction of NF-kappa B DNA-binding activity. Although the intact beta interferon promoter was only weakly stimulated by phorbol ester or TNF-alpha, multimers of the PRDII NF-kappa B-binding domain were inducible by both agents. TNF-alpha was able to increase expression of the HIV LTR in T cells, but in monocytic cells, TNF-alpha did not induce the HIV LTR above a constitutive level of activity. This level of NF-kappa B-independent activity appears to be sufficient for virus multiplication, since TNF-alpha treatment had no effect on the kinetics of de novo HIV type 1 (HIV-1) infection and viral RNA production in U937 cells. However, in Jurkat cells, TNF-alpha dramatically enhanced the spread of HIV-1 through the cell population and increased viral RNA synthesis, indicating that in T cells HIV-1 multiplication was stimulated by TNF-alpha treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2204723      PMCID: PMC247959     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone.

Authors:  K A Clouse; D Powell; I Washington; G Poli; K Strebel; W Farrar; P Barstad; J Kovacs; A S Fauci; T M Folks
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

2.  Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements.

Authors:  R Grosschedl; D Baltimore
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

3.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV.

Authors:  D Klatzmann; E Champagne; S Chamaret; J Gruest; D Guetard; T Hercend; J C Gluckman; L Montagnier
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

4.  AIDS-associated retroviruses (ARV) can productively infect other cells besides human T helper cells.

Authors:  J A Levy; J Shimabukuro; T McHugh; C Casavant; D Stites; L Oshiro
Journal:  Virology       Date:  1985-12       Impact factor: 3.616

5.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus.

Authors:  A G Dalgleish; P C Beverley; P R Clapham; D H Crawford; M F Greaves; R A Weiss
Journal:  Nature       Date:  1984 Dec 20-1985 Jan 2       Impact factor: 49.962

6.  Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.

Authors:  C M Gorman; L F Moffat; B H Howard
Journal:  Mol Cell Biol       Date:  1982-09       Impact factor: 4.272

7.  Human lymphotoxin and tumor necrosis factor genes: structure, homology and chromosomal localization.

Authors:  G E Nedwin; S L Naylor; A Y Sakaguchi; D Smith; J Jarrett-Nedwin; D Pennica; D V Goeddel; P W Gray
Journal:  Nucleic Acids Res       Date:  1985-09-11       Impact factor: 16.971

8.  Slow, persistent replication of lentiviruses: role of tissue macrophages and macrophage precursors in bone marrow.

Authors:  H E Gendelman; O Narayan; S Molineaux; J E Clements; Z Ghotbi
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

9.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  13 in total

1.  Identification by in vivo genomic footprinting of a transcriptional switch containing NF-kappaB and Sp1 that regulates the IkappaBalpha promoter.

Authors:  M Algarté; H Kwon; P Génin; J Hiscott
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Coordinate enhancement of cytokine gene expression in human immunodeficiency virus type 1-infected promonocytic cells.

Authors:  M D'Addario; A Roulston; M A Wainberg; J Hiscott
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

3.  Differential partial activation phenotype and production of tumour necrosis factor-α by conventional dendritic cells in response to lipopolysaccharide in HIV+ viraemic subjects and HIV+ controllers.

Authors:  R Camacho-Sandoval; P M Del Río Estrada; A Rivero-Arrieta; G Reyes-Terán; L C Bonifaz
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

4.  Transdominant mutants of I kappa B alpha block Tat-tumor necrosis factor synergistic activation of human immunodeficiency virus type 1 gene expression and virus multiplication.

Authors:  P Beauparlant; H Kwon; M Clarke; R Lin; N Sonenberg; M Wainberg; J Hiscott
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

5.  Viral induction of the human beta interferon promoter: modulation of transcription by NF-kappa B/rel proteins and interferon regulatory factors.

Authors:  E Garoufalis; I Kwan; R Lin; A Mustafa; N Pepin; A Roulston; J Lacoste; J Hiscott
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

6.  Chronic human immunodeficiency virus type 1 infection stimulates distinct NF-kappa B/rel DNA binding activities in myelomonoblastic cells.

Authors:  A Roulston; P Beauparlant; N Rice; J Hiscott
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

7.  Differential susceptibilities of U-937 cell clones to infection by human immunodeficiency virus type 1.

Authors:  F Boulerice; R Geleziunas; S Bour; H L Li; M D'Addario; A Roulston; J Hiscott; M A Wainberg
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

8.  Characterization of a functional NF-kappa B site in the human interleukin 1 beta promoter: evidence for a positive autoregulatory loop.

Authors:  J Hiscott; J Marois; J Garoufalis; M D'Addario; A Roulston; I Kwan; N Pepin; J Lacoste; H Nguyen; G Bensi
Journal:  Mol Cell Biol       Date:  1993-10       Impact factor: 4.272

9.  Constitutive phosphorylation and turnover of I kappa B alpha in human T-cell leukemia virus type I-infected and Tax-expressing T cells.

Authors:  J Lacoste; L Petropoulos; N Pépin; J Hiscott
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

Review 10.  Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors.

Authors:  A Roulston; R Lin; P Beauparlant; M A Wainberg; J Hiscott
Journal:  Microbiol Rev       Date:  1995-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.